Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing

Basit Öğe Kaydı
dc.authoridKarav, Sercan / 0000-0003-4056-1673
dc.contributor.authorAbavisani, Mohammad
dc.contributor.authorKhoshrou, Alireza
dc.contributor.authorEshaghian, Souzan
dc.contributor.authorKarav, Sercan
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2025-01-27T20:31:41Z
dc.date.available2025-01-27T20:31:41Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractSince its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilising their established safety profiles and pharmacological data to swiftly provide effective treatments against resistant pathogens. Several drugs, including otilonium bromide, penfluridol, eltrombopag, ibuprofen, and ceritinib, have demonstrated potent antibacterial activity against multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, and inhibit bacterial growth. The combination of repurposed drugs with conventional antibiotics can reduce the required dosage of individual drugs, mitigate side effects, and delay the development of resistance, making it a promising strategy against MDR bacteria such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Despite its promise, drug repurposing faces challenges such as potential off-target effects, toxicity, and regulatory and intellectual property issues, necessitating rigorous evaluations and strategic solutions. This article aims to explore the potential of drug repurposing as a strategy to combat antibiotic resistance, examining its benefits, challenges, and future prospects. We address the legal, economic, and practical challenges associated with repurposing existing drugs, highlight successful examples, and propose solutions to enhance the efficacy and viability of this approach in combating MDR bacterial infections.
dc.identifier.doi10.1080/1061186X.2024.2424895
dc.identifier.issn1061-186X
dc.identifier.issn1029-2330
dc.identifier.pmid39485073
dc.identifier.scopus2-s2.0-85209655643
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1080/1061186X.2024.2424895
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23237
dc.identifier.wosWOS:001353274100001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Drug Targeting
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectDrug repositioning
dc.subjectdrug resistance, microbial
dc.subjectGram-negative bacteria
dc.subjectinfection
dc.subjectmycobacteria
dc.subjecttuberculosis, multidrug-resistant
dc.titleOvercoming antibiotic resistance: the potential and pitfalls of drug repurposing
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Sercan Karav_Review.pdf
Boyut:
3.6 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Moleküler Biyoloji ve Genetik Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu